Life Sciences sector is delivering £10 billion into Northern Powerhouse


A review has been commissioned by UK Trade and Investment (UKTI) to highlight the investment opportunity in Life Sciences across the North of England. It will be used to help drive inward investment into the North of England’s thriving life sciences sector.

The Northern Powerhouse Life Sciences investment proposition builds on sectoral data collated by N8 and NHSA in their Right Time, Right Place report on the sector and the excellent collaborative activities across the academic-medical-industrial triumvirate in the region. Highlights include:

  • Life sciences in the North of England contribute £10.8 billion to the UK economy each year
  • Over 1,000 life sciences businesses in the North support over 38,000 high skilled jobs
  • Northern Powerhouse companies export over £8.1 billion of medicinal and pharmaceutical products per year

Launching the proposition at the BioTrinity Conference in London, Life Sciences Minister George Freeman said: “This data shows that the UK’s £56bn life sciences industry is a powerhouse in the Northern economy.

“Through our life sciences strategy we are creating jobs, opportunities and security across the North. With its world-leading universities, innovative life sciences companies and millions of NHS patients across the region, the North has unique capabilities with excellent growth potential for international investors.”


The proposition showcases the world class facilities that the North has to offer such as:

  • the £38 million National Biologics Manufacturing Centre within the Centre for Process Innovation (CPI) which will host the £20 million CPIBiologics Factory of the Future
  • Alderley Park in Cheshire – with over £550 million invested in world-class facilities and infrastructure over the past decade, Alderley Park is one of the best invested bioscience R&D sites in Europe, and is now home to:
    • the £4 million UK AMR Centre – a £4 million investment in AMR therapeutics development at Alderley Park
    • Medicines Discovery Catapult – the Catapult, being established at Alderley Park, will operate at the earliest stages of medicines development, developing and validating new technologies for testing of potential medicines before human trials and supporting the important UK strength in pharmaceutical, biotechnology and contract research organisations
  • The North also boasts one of the Europe’s strongest clusters in biological, medical and surgical manufacturing with Eli Lilly, Allergan, Fujifilm Diosynth Biotechnologies, Seqirus, JRI Orthopaedics, and DePuy Synthes based there

NP great britain (2)